Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM
Lonial, Sagar, Richard, Shambavi, Matous, Jeffrey V, Yee, Andrew J., Shah, Urvi, Mehta-Shah, Neha, Martin, Thomas, Muchtar, Eli, Ailawadhi, Sikander, Richardson, Paul G., Bhutani, Manisha, Perino, Samantha, Kirby, Jason, Agafonov, Roman V., Chaturvedi, Prasoon, Class, Bradley, Schnaderbeck, Matthew, Palmer, Michael R., Gorman, Cathleen, Schoenborn-Kellenberger, Oliver, Hoerres, Amanda, Fisher, Stewart L., Pollock, Roy M., Crystal, Adam, Mahler, Michelle, Bardeja, Jesus
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article